Corbus Pharmaceuticals stock falls 2.58% to $9.82, underperforming competitors
Updated
Updated · MarketWatch · Apr 28
Corbus Pharmaceuticals stock falls 2.58% to $9.82, underperforming competitors
9 articles · Updated · MarketWatch · Apr 28
Corbus Pharmaceuticals shares closed at $9.82 on Tuesday, down 2.58%, with trading volume at 209,044, below the 50-day average.
The stock significantly underperformed rivals as Vanda Pharmaceuticals rose 0.74%, while Fortress Biotech and Viking Therapeutics declined less sharply.
Corbus remains 52.24% below its 52-week high of $20.56, reflecting broader market weakness as the NASDAQ fell 0.90% and the Dow Jones slipped 0.05%.
With a $42 price target, is Corbus Pharmaceuticals stock a major bargain or a value trap?
Can Corbus's new cancer drug truly challenge the market leader Astellas Pharma?
Why are insiders selling shares if Corbus's pipeline and analyst outlook appear so strong?
What hidden risks could derail Corbus's promising clinical trials despite positive early data?
Will upcoming ASCO data be the catalyst to reverse the stock's recent underperformance?
How will a non-incretin obesity drug compete against the dominant GLP-1 therapies?